La nuova combinazione di TALVEY®▼ (talquetamab) e TECVAYLI®▼ (teclistamab) comporta alti tassi di risposta e risposte durature in pazienti refrattari alla tripla classe con mieloma multiplo recidivato o refrattario, compresi i pazienti con malattia extramidollare
October 04, 2024 16:28 ET
|
Janssen Cilag International NV
I dati dello studio sperimentale di Fase 1b RedirecTT-1 dimostrano un profilo di sicurezza coerente con le monoterapie talquetamab e teclistamab1 BEERSE, BELGIO, Oct. 04, 2024 (GLOBE NEWSWIRE) --...
Neue Kombination aus TALVEY®▼(talquetamab) und TECVAYLI®▼ (teclistamab) deutet auf hohe Ansprechraten und ein dauerhaftes Ansprechen bei Tripe-Class-refraktären Patienten mit rezidiviertem oder refraktärem Multiplem Myelom, einschließlich Patienten mit extramedullärer Erkrankung
October 04, 2024 16:28 ET
|
Janssen Cilag International NV
Daten aus der Phase-Ib-Forschungsstudie RedirecTT-1 zeigen ein mit dem von talquetamab und teclistamab-Monotherapien vergleichbares Sicherheitsprofil1 BEERSE, BELGIEN, Oct. 04, 2024 (GLOBE...
La nouvelle association de TALVEY®▼ (talquétamab) et TECVAYLI®▼ (teclistamab) suggère des taux de réponse élevés et des réponses durables chez les patients réfractaires à trois classes de médicaments atteints d’un myélome multiple récidivant ou réfractaire, y compris les patients atteints d’une maladie extramédullaire
October 04, 2024 16:28 ET
|
Janssen Cilag International NV
Les données issues de l’étude expérimentale de Phase Ib RedirecTT-1 démontrent un profil d’innocuité cohérent avec les monothérapies par talquétamab et teclistamab1 BEERSE, BELGIQUE, 04 oct. 2024 ...
Nouscom to Present Updated Positive Data on NOUS-209’s Potential to ‘Intercept’ Cancer in Lynch Syndrome Carriers at SITC 2024
October 04, 2024 09:00 ET
|
Nouscom Srl
BASEL, Switzerland – 4th October 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
October 03, 2024 08:00 ET
|
Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
October 03, 2024 03:00 ET
|
Enara bio
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio’s EDAPT®...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Immune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market Insights Inc.
October 01, 2024 05:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Immune Checkpoint Inhibitors Market size reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032...
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
September 30, 2024 08:00 ET
|
Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer